Monocytes transduced with lentiviral vectors expressing hepatitis C virus non-structural proteins and differentiated into dendritic cells stimulate multi-antigenic CD8(+) T cell responses

Vaccine
Adan C JirmoRenata Stripecke

Abstract

Halting the spread of hepatitis C virus (HCV) and also eradicating HCV in subjects with chronic infection are major goals for global health. To this end, several years of research on HCV vaccine development have led to the conclusion that multi-antigenic and multi-functional vaccine types are necessary for effectiveness against HCV infection. In this study, we evaluated lentiviral vectors (LV) expressing clusters of HCV structural (LV-HCV-S) and non-structural (LV-HCV-NS) genes for future vaccine development. Batches of high titer LV were used to transduce differentiated dendritic cells (DC) and monocytes. We report successful delivery of HCV gene clusters, particularly into monocytes, leading to >80% LV-HCV-NS and >70% LV-HCV-S and transduced cells, respectively. Intracellular expression of HCV proteins in monocyte-derived DC resulted in immunophenotypic changes, such as downregulation of CD83 and CD86. Monocytes expressing NS proteins and differentiated into DC stimulated allogeneic and autologous CD8(+) and CD4(+) T cells in vitro and resulted in antigen-specific CD8(+) T cell responses against NS3, NS4a and NS5b. Hence, lentiviral-mediated expression of the multi-antigenic HCV-NS cluster in monocytes subsequently differenti...Continue Reading

References

Jul 1, 1994·The Journal of Experimental Medicine·N RomaniG Schuler
Sep 25, 1999·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·V LamonacaC Ferrari
Aug 10, 2000·Molecular Therapy : the Journal of the American Society of Gene Therapy·B FehseC Baum
Apr 16, 2003·Journal of Medical Virology·A GruberF Wong-Staal
Jun 5, 2003·The Journal of Clinical Investigation·Christoph EsslingerH Robson MacDonald
Jun 13, 2003·Pathologie-biologie·R M Steinman
Sep 16, 2003·Journal of Immunotherapy·Richard C KoyaRenata Stripecke
Nov 26, 2003·Antiviral Research·Ralf BartenschlagerSandra Sparacio
Mar 2, 2005·Nature Reviews. Immunology·Barbara Rehermann, Michelina Nascimbeni
Nov 29, 2005·Cancer Immunology, Immunotherapy : CII·Luciene LopesMary Collins
Dec 13, 2005·Seminars in Oncology·Antoni Ribas
Jan 21, 2006·Cancer Research·Laurence ChapatteFrédéric Lévy
Oct 28, 2006·Annual Review of Immunology·Lynn B Dustin, Charles M Rice
Mar 22, 2007·Molecular Therapy : the Journal of the American Society of Gene Therapy·Richard C KoyaRenata Stripecke
May 17, 2007·Molecular Therapy : the Journal of the American Society of Gene Therapy·Takahiro KimuraRenata Stripecke
Mar 3, 2009·Expert Review of Vaccines·Françoise Stoll-KellerThomas F Baumert

❮ Previous
Next ❯

Citations

Jan 1, 2011·Therapeutic Delivery·Anja Krause, Stefan Worgall
Feb 18, 2011·Journal of Gastroenterology·Angela Dolganiuc, Gyongyi Szabo
Mar 12, 2010·Expert Review of Vaccines·Mudita PinchaRenata Stripecke
Jul 31, 2012·Antiviral Research·Peng Peng IpToos Daemen
Jul 27, 2017·Virus Genes·Henning OlbrichRenata Stripecke

❮ Previous
Next ❯

Related Concepts

Related Feeds

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.